Cheil Bio KRX:052670KOSDAQ
제일바이오 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked0since Sep 11
In Q2 2026, Cheil Bio reported revenue of ₩5.1bn, up 33.5% year on year, and operating profit of ₩343m. Cheil Bio (제일바이오) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals Turnaround Screener
Cheil Bio quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩5.1bn | +33.5% | ₩343m margin 6.7% | ₩1.4bn |
| Q1 2026 | ₩3.5bn | +2.3% | −₩338m margin −9.6% | −₩362m |
| Q4 2025 derived | ₩3.8bn | – | ₩34m margin 0.9% | ₩14m |
| Q3 2025 | ₩3.3bn | -48.3% | −₩166m margin −5.0% | ₩67m |
| Q2 2025 | ₩3.9bn | +18.2% | −₩127m margin −3.3% | −₩48m |
| Q1 2025 | ₩3.5bn | +10.1% | −₩405m margin −11.7% | −₩265m |
| Q4 2024 derived check units | −₩6.1bn | – | −₩333m | −₩6m |
| Q3 2024 | ₩6.4bn | +89.6% | ₩23m margin 0.4% | ₩136m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Cheil Bio top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Cheil Bio news Korean headlines
No articles yet.